Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Nobel Prize winner continues to search for more immune checkpoints that can be blocked.
Innovative approaches can kill tumor cells more effectively and with fewer side effects.
Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.
Metastatic kidney cancer patients with greater microbial diversity had better outcomes with immunotherapy.
Margaret has never stopped living and enjoying her life despite her disease and the side effects of her medication.
“I feel so fortunate that I’ve been given a second chance," says Schuman, who was diagnosed with melanoma in 2018.
It’s possible to identify these individuals in advance, helping them to focus on clinical trials of more effective treatments.
“This may be the solution to many problems,” says researcher Rizwan Haq, MD, PhD.
The combination of chemoimmunotherapy with a targeted drug represents a step toward a new standard of care for people with CLL.
New research asks if an alternative dosing schedule can produce the same effects with fewer side effects.
The method identifies which targeted therapies, inadequate on their own, can be paired up to kill non-responsive cancers.
In two large clinical trials, an immune checkpoint inhibitor combined with a targeted therapy had better outcomes than the standard of care.
Researchers called the results of treatment using Venclexta (venetoclax) and Vidaza (azacitidine) “remarkably impressive.”
The study used two FDA-approved drugs to the pre-leukemic cells while leaving healthy stem cells alone.
When Derrick tells the story of his journey with melanoma, the overwhelming theme is gratitude—for doctors, researchers and loved ones.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.